About The Study: In this secondary analysis of a randomized clinical trial, patients who received at least one COVID-19 vaccine dose after acute coronary syndromes had similar rates of the primary composite end point and major adverse cardiovascular events (MACE) compared with unvaccinated patients. However, retrospective studies have demonstrated a short-term reduction in MACE risk after COVID-19 vaccination.
About The Study: In this secondary analysis of a randomized clinical trial, patients who received at least one COVID-19 vaccine dose after acute coronary syndromes had similar rates of the primary composite end point and major adverse cardiovascular events (MACE) compared with unvaccinated patients. However, retrospective studies have demonstrated a short-term reduction in MACE risk after COVID-19 vaccination.
Corresponding Author: To contact the corresponding author, Henrique Andrade R. Fonseca, Ph.D., email henrique.fonseca@einstein.br.
To access the embargoed study: Visit our For The Media website at this link
(doi:10.1001/jamanetworkopen.2024.13946)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
Journal
JAMA Network Open
Discover more from Science
Subscribe to get the latest posts sent to your email.
